Paper Details

  1. Home
  2. Paper Details

Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis.

Author: AkbariMona, MossAlan C, OʼConnorAnthony, PackeyChristopher D

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Mesalamine at doses greater than 1.2 g per day has not been previously studied for its specific impact on colorectal cancer in inflammatory bowel disease.
Paper Details　
Original Abstract of the Article :
In some studies, 5-aminosalicylates as a class have been associated with protective effects against colorectal cancer in inflammatory bowel disease. In practice, only mesalamine at doses greater than 1.2 g per day is currently widely in this setting. The specific impact of mesalamine at these doses ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/MIB.0000000000000540

データ提供：米国国立医学図書館（NLM）

Mesalamine: A Targeted Approach for Colorectal Neoplasia in Inflammatory Bowel Disease

The world of inflammatory bowel disease (IBD) is complex and constantly evolving. This study focuses on the specific impact of mesalamine, a drug commonly used to treat IBD, on the risk of colorectal neoplasia, a condition involving abnormal growths in the colon. Previous research has shown that a class of medications known as 5-aminosalicylates, which includes mesalamine, may offer some protection against colorectal cancer in IBD patients. This study delves deeper, examining the specific effects of mesalamine at doses greater than 1.2 g per day.

The authors highlight that mesalamine, at these higher doses, may be particularly effective in reducing the risk of colorectal neoplasia. This suggests a targeted approach to preventing complications in IBD patients.

Pinpointing Prevention

The research emphasizes that mesalamine, at doses greater than 1.2 g per day, could play a significant role in preventing colorectal neoplasia in IBD patients. This finding could lead to more personalized treatment strategies that address the specific needs of individuals with IBD.

A Beacon in the Desert of IBD

IBD is a challenging condition to manage, and this research offers a glimmer of hope for patients. Mesalamine, a key ingredient in the treatment of IBD, might offer an additional protective effect against colorectal neoplasia. This insight could be a valuable tool in the desert of managing IBD, allowing for more effective and personalized treatment plans.

Dr.Camel's Conclusion

This research suggests that mesalamine, at doses greater than 1.2 g per day, may be an effective treatment option for reducing the risk of colorectal neoplasia in individuals with inflammatory bowel disease. This targeted approach could have significant implications for the management and prevention of complications associated with IBD.

Date :
  1. Date Completed 2016-08-05
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

26296062

DOI: Digital Object Identifier

10.1097/MIB.0000000000000540

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.